New: our own Hairmetry line. Every ingredient explained

Topic

Androgens, anabolic steroids and hair

Testosterone and other androgens thicken beard and body hair but can start or speed up pattern hair loss in people who are genetically prone.

hair lossreceding hairlinethinningbrows lashes beard

This is a harm-reduction page. It gives no doses, cycles or sourcing, and it does not recommend using androgens for any hair goal.

Key takeaways

  • Androgens do two opposite things: they thicken beard and body hair and, in people with the genetic susceptibility, shrink scalp follicles. Same hormone, different follicle response. Randall 2000; Inui 2013
  • Adding testosterone can start or speed up pattern hair loss in people who are prone to it. In a 2023 clinic cohort, transgender men on masculinising therapy had about 2.5 times the rate of pattern hair loss seen in cisgender women (adjusted incidence rate ratio 2.50, 95% CI 1.71 to 3.65), similar to cisgender men. Gao 2023
  • Feminising therapy (estradiol and/or antiandrogens) can reduce facial and body hair and can improve pattern hair loss, according to a 2023 systematic review whose studies mostly used subjective grading. Tang 2023
  • Finasteride and dutasteride protect scalp hair from testosterone's conversion to DHT, but some synthetic androgens do not need that conversion to act, so a 5-ARI would not be expected to protect against them (rat data). Attardi 2010
  • High-quality studies of non-medical anabolic steroid use and hair loss are scarce, and we found only old narrative reviews. Treat claims that a particular compound is "safe for hair" as unproven.
  • Hair loss driven by androgens is partly preventable but not fully reversible: follicles that have miniaturised for years may not fully recover. See DHT and pattern hair loss.

The science

Why the same hormone does opposite things. Beard and body follicles grow thicker with androgen while genetically susceptible scalp follicles shrink. The difference lies in the follicle's receptors and local enzymes, not in the hormone. Randall 2000

Testosterone therapy. Reviews of gender-affirming hormone therapy describe testosterone in transgender men increasing facial and body hair and inducing or accelerating pattern hair loss. Tang 2023 A 2026 narrative review concludes that pattern loss in transgender men usually begins after masculinising therapy and follows a course like that of cisgender men, that oral minoxidil is central to management, and that 5-ARIs appear more relevant in transgender men than in transgender women with suppressed testosterone. Ramos-Rodriguez 2026 In a small 2025 case series (3 men, 6 months), finasteride in transgender men on testosterone showed at least one Norwood stage of improvement, but two participants resumed menstruation, so effects on the intended masculinisation need study. Tominaga 2025

Feminising therapy. In the 2023 cohort, transgender patients on feminising therapy had a pattern-loss rate not significantly different from cisgender men but higher than cisgender women (adjusted rate ratio 1.91, 95% CI 1.25 to 2.92), consistent with prior androgen exposure. Gao 2023; Ramos-Rodriguez 2026

Androgens that skip DHT. Compounds such as dimethandrolone and 11-beta-methyl-19-nortestosterone, which are being developed as male hormonal contraceptives, kept their androgenic potency in castrated rats even when dutasteride blocked 5-alpha-reductase. The authors noted that 5-alpha-reduced androgens might raise the risk of baldness and acne, which is why they tested this. Attardi 2010 Whether such compounds cause scalp hair loss in people has not been shown in studies we found.

What it means for your hair

  • Genetic susceptibility is the main variable: a family history of early balding raises the chance that androgens will thin the scalp.
  • Women and people with ovaries on testosterone: scalp thinning can appear alongside voice deepening and facial hair. Discuss hair goals with the prescribing clinician before starting, since minoxidil, and in some cases 5-ARIs, are managed differently in this group. Ramos-Rodriguez 2026
  • Women with PCOS or other excess androgen: see spironolactone, oral contraceptives and the antiandrogen comparison.

Myths and facts

  • Myth: DHT is the only androgen that matters for hair. Fact: testosterone also binds the receptor, and some synthetic androgens work without being converted to DHT. Attardi 2010; Grino 1990
  • Myth: finasteride lets you use any androgen without losing hair. Fact: it lowers DHT, not other androgen effects, and has its own side-effect profile; see finasteride and post-finasteride syndrome.
  • Myth: creatine raises DHT and makes you bald. Fact: a 12-week trial found no change in DHT or hair; see creatine.

Bottom line

If you are prescribed testosterone, tell the prescriber about your hair goals, family history and any plan to use finasteride, dutasteride or minoxidil before you start, so options can be planned. If you use androgens without a prescription, products vary in content and we have no verified evidence about their effect on hair. The main risks of non-medical use (heart, hormones, fertility) are outside this page. If scalp thinning appears, early evaluation matters more than waiting, because the earlier treatment starts the more hair can be saved. Discuss with a doctor.

Studies 8

Randall VA. The hair follicle: a paradoxical androgen target organ. Horm Res. 2000

Design
review
Who
review of androgen action on hair follicles

Tested: review

Result: Androgens enlarge beard follicles and shrink balding scalp follicles; they act mainly through the dermal papilla, and the differences are thought to be set in the embryo.

Read the study ↗

Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 2013

Design
review
Who
review of androgen action on hair follicles

Tested: review

Result: Androgens induce IGF-1 from beard papilla cells and TGF-beta1, TGF-beta2, DKK-1 and IL-6 from balding papilla cells; follicles hold both enzyme types, receptors and co-activators.

Read the study ↗

Gao JL et al. Androgenetic alopecia incidence in transgender and gender diverse populations. J Am Acad Dermatol. 2023

Design
cohort
People
37,826
Who
transgender and gender-diverse patients vs cisgender patients in a clinic cohort

Tested: masculinising or feminising hormone therapy

Result: Transgender men on masculinising therapy had about 2.5 times the AGA rate of cisgender women (adjusted incidence rate ratio 2.50); feminising therapy rate was higher than cisgender women (1.91) but not different from cisgender men.

Read the study ↗

Tang GT et al. Effect of gender-affirming hormone therapy on hair growth: systematic review. Clin Exp Dermatol. 2023

Design
systematic review
Who
people on gender-affirming hormone therapy

Tested: testosterone or feminising therapy

Result: Testosterone may increase facial and body hair and induce or accelerate AGA; feminising therapy can reduce facial and body hair; most studies used subjective grading.

Read the study ↗

Ramos-Rodriguez D et al. Androgenetic alopecia in transgender and gender-diverse individuals: narrative review. Dermatol Ther (Heidelb). 2026

Design
review
Who
transgender and gender-diverse people

Tested: review

Result: AGA in transgender men most often begins after masculinising therapy and follows a course like that of cisgender men; oral minoxidil is central to management.

Read the study ↗

Tominaga Y et al. Finasteride for transgender men with androgenetic alopecia: case series. J Med Case Rep. 2025

Design
case series
People
3
Duration
6 months
Who
transgender men on testosterone

Tested: finasteride

Result: At least one Norwood stage improvement, but two participants resumed menstruation.

Read the study ↗
Show 2 more studies

Attardi BJ et al. Dimethandrolone (DMA) and 11beta-methyl-19-nortestosterone (11beta-MNT) do not require 5alpha-reduction to exert their maximal androgenic effect. J Steroid Biochem Mol Biol. 2010

Design
animal
Who
castrated rats

Tested: synthetic androgens with and without dutasteride

Result: The compounds kept their androgenic potency even when 5-alpha-reductase was blocked.

Read the study ↗

Grino PB et al. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990

Design
in vitro
Who
human androgen receptor in cells

Tested: testosterone vs DHT binding

Result: DHT binds the receptor about 2-fold more tightly than testosterone and dissociates about 5-fold more slowly.

Read the study ↗